Upload
maninder-ahuja
View
521
Download
1
Embed Size (px)
Citation preview
ASTHMA IN PREGNANCYASTHMA IN PREGNANCY
Dr.Manider Ahuja Dr.Manider Ahuja Director Ahuja Hospital and Infertility CentreDirector Ahuja Hospital and Infertility Centre
VP FOGSI 2013-2014VP FOGSI 2013-2014President IMS 2014-2015President IMS 2014-2015
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 11
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 22
THANKS TO PATNA CHAPTER
I BRING GREETINGS FROM HARYANA
Dr.Maninder Ahuja PRESENT
DESIGNATION:
• DIRECTOR AHUJA HOSPITAL AND INFERTILITY CENTRE• 40 yrs work for women from ADOLESCENTS TO MENOPAUSE
PRESENT AFFILIATION:
CO EDITOR OF JOURNAL OF MID LIFE HEALTH PRESIDENT INDIAN MENOPAUSE SOCIETY (2014-2015)Deputy SECRETARY GENERAL OF SOUTH ASIAN FEDERATION OF
MENOPAUSE SOCIETIES 2013-2015Vice president FOGSI 2013-2014National co ordinator cervical cancer screening programFounder chpater secretary IMS FARIDABADPRESIDENT FOGS Chairperson Haryana chapter of ISAR& ISPAT President ISPAT HARYNA CHAPTER
MAJOR ACHIEVEMENTS:
(HONOURS)(AWARDS)(PUBLICATIONS)
EDITOR OF BOOK” PREMALIGNANT LESIONSOF CERVIX-EARLY DIAGNOSIS AND MANAGEMENT”
AUTHOR OF BOOK “STEP BY STEP MANAGEMENTOF MENOPAUSE
SEVERAL CHAPTERS IN MANY TEXT BOOKS MANY DVDS ON “ PRESCRIPTION OF EXERCISE”
BEST FOGSIAN AWARD 2008, BEST PRESENTATION AWARD, BEST ROTARIAN AWARD
Co editor for Jounrnal Of Midlife Health and peer reviewer for SAFOMS Journal
PHOTO
17/12/1717/12/17DR.MANINDER DR.MANINDER AHUJA VP AHUJA VP FOGSI2013-FOGSI2013-20142014
33
RESEARCH
Original Research In the JMH On Age of Menopause
AUTHOR • Author of Book “ Step by Step
Management of Menopause• Many Chapters in Text Book of Jeffcott • Chapters in FOGSI PUBLICATIONS • In many FOGSI FOCUSES• On the FOGSI Web Site Author of Life
style Modificcations
Editor • CX Cancer Screening and Management of
Premalignant Lesions of CX• Editor of ISARCON Series of workshops
manuals on infertility management from A –Z
PUBLICATIONS
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 44
17/12/1717/12/17
DR
.MA
NIN
DER
AH
UJA
VP FO
GSI 2013-2014
DR
.MA
NIN
DER
AH
UJA
VP FO
GSI 2013-2014
55
DVDs ONEXERCISE
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 66
Editor of ISARCONManuals
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 77
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 88
ASTHMA IN PREGNANCY ASTHMA IN PREGNANCY Dr.Manider Ahuja Dr.Manider Ahuja
Director Ahuja Hospital and Infertility CentreDirector Ahuja Hospital and Infertility CentreVP FOGSI 2013-2014VP FOGSI 2013-2014
President IMS 2014-2015President IMS 2014-2015
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 99
DISCUSSION WOULD BE DISCUSSION WOULD BE ONON
Risk and Risk and PrevalencePrevalence
PathophysiologyPathophysiology
D/DD/D
Examination Examination findings findings
Etiology Etiology
InvestigationsInvestigations
Chest X-rayChest X-ray
PFT PFT
PharmacologyPharmacology
Hospital careHospital care
Admissions and Admissions and discharge discharge
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 1010
introductionintroductionAsthma is result of Chronic inflammattion of air ways that Asthma is result of Chronic inflammattion of air ways that
results in air way obstruction anad can be triggered by various results in air way obstruction anad can be triggered by various stimulistimuli
Most common chronic condition of pregnancyMost common chronic condition of pregnancy
Episodic,For short periods a few min to hours Episodic,For short periods a few min to hours
Prevalence in general public is 4-5% in pregnancy .1-4%Prevalence in general public is 4-5% in pregnancy .1-4%
Mortality 2 persons per 100000Mortality 2 persons per 100000
Rey E, Boulet LP. Asthma in pregnancy. BMJ. 2007 Mar 17. 334(7593):582-5. [Medline]. [Full Text].
Sly RM, O'Donnell R. Stabilization of asthma mortality. Ann Allergy Asthma Immunol. 1997 Apr. 78(4):347-54. [Medline].
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 1111
TRIGGERING factors in TRIGGERING factors in Asthma Asthma
Genetic and environmentalGenetic and environmental
Allergens, including pollens, house-dust mites, cockroach antigen, animal dander, molds, and Hymenoptera stings
Irritants, including cigarette smoke, wood smoke, air pollution, strong odors, occupational dust, and chemicals
Medical conditions, including viral upper respiratory tract infections, sinusitis, esophageal reflux, andAscaris infestations
Asthma is a disease of the airways by reversible airway obstruction and hyper- reactivity to a variety of stimuli.
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 1212
ALLERGENS ALLERGENS
Drugs and chemicals, including aspirin, nonsteroidal anti-inflammatory drugs, beta blockers, radiocontrast media, and sulfites
Exercise (see Exercise
Cold air,flu rhinitis
Menses
Emotional stress
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 1313
Pregnancy out Pregnancy out comes in Asthma comes in Asthma
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 1414
PregNANCY PregNANCY outcomes outcomes
Preeclampsia
PIH
Ut. hemorrhage
Preterm labor
Premature birth
Unplaned LSCS
Gestational Diabetes
Congenital anomalies
Fetal growth restriction
Low birth weight
Neonatal hypoglycemia, seizures, tachypnea, and neonatal intensive care unit (ICU) admission
These changes are seen only in historical studies and where corticosteroids were not used
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 1515
PHYSIOLOGICAL CHANGES IN PHYSIOLOGICAL CHANGES IN RESP SYSTEM IN PREG RESP SYSTEM IN PREG
Resp rate and vital capacity no change Resp rate and vital capacity no change
Tidal volume, minute ventilation increased (40%),
Minute oxygen uptake (20%) increase,
With a resultant decrease in functional residual capacity and residual volume of air as a consequence of the elevated diaphragm.
In addition, airway conductance is increased
Total pulmonary resistance is reduced, possibly as a result of the influence of progesterone.
During pregnancy the severity of asthma remains stable in a third of women, worsens in another third, and improves in the remaining third.w7
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 1717
changes IN changes IN RESPIRATORY SYSTEM IN RESPIRATORY SYSTEM IN
PREGNANCYPREGNANCYDecreased co2 pressureDecreased co2 pressure
Decreased bicarbonate Decreased bicarbonate
Increased phIncreased ph
Normal pco2 in pregnancy means respiratory failure Normal pco2 in pregnancy means respiratory failure
More effective gas exchageMore effective gas exchage
Respiratory alkalosis and hyperventilatory stage Respiratory alkalosis and hyperventilatory stage
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 1818
PATHOPHYSIOLOGY Asthma PATHOPHYSIOLOGY Asthma
Inflammation of the airways, With an abnormal accumulation
of eosinophils, lymphocytes, mast cells, macrophages, dendritic cells, and myofibroblasts.
This leads to a reduction in airway diameter caused by smooth muscle contraction,
Vascular congestion, Bronchial wall edema, Thick secretions.
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 1919
Asthma Asthma characteristicscharacteristics
Shortness of breath , wheezing and cough determine severity
Chest tightness
Nocturnal awakenings
Recurrent episodes of symptom complex
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 2020
HISTORY AND HISTORY AND PHYSCIAL FINDINGSPHYSCIAL FINDINGS
Exacerbations possibly provoked by nonspecific stimuli
Personal or family history of other atopic disease (eg, hay fever, eczema)
Tachypnea
Retraction (sternomastoid, abdominal, pectoralis muscles)
Agitation, usually a sign of hypoxia or respiratory distress
Pulsus paradoxicus (>20 mm Hg)
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 2121
PULMONARY FINDINGSPULMONARY FINDINGS
Diffuse wheezes - Long, high-pitched sounds on expiration and, occasionally, on inspiration)
Diffuse rhonchi - Short, high- or low-pitched squeaks or gurgles on inspiration and/or expiration
Bronchovesicular sounds
Expiratory phase of respiration equal to or more prominent than inspiratory phase
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 2222
SIGNS OF RESP FAILURE SIGNS OF RESP FAILURE
Alteration in the level of consciousness, such as lethargy, which is a sign of respiratory acidosis and fatigue
Abdominal breathing
Inability to speak in complete sentences
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 2323
Investigations Investigations
CBC-anemia, thrombocytopenia or infectionCBC-anemia, thrombocytopenia or infection
Blood gases ABG-to see oxygenation Blood gases ABG-to see oxygenation
ABG values: pH = 7.4-7.45, pO2= 95-105 mm Hg, pCO2 = 28-32 mm Hg, and bicarbonate = 18-31 mEq/L.
XRAY Chest XRAY Chest
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 2424
Chest x-rayChest x-rayChest radiography is indicated
when the other coexistent conditions, such as pneumonia, barotrauma, CHF, or chronic obstructive pulmonary disease, are likely.
Chest radiographs (2 views) with a shielded maternal abdomen expose the fetus to approximately 0.00005 rad.
17/12/1717/12/17DR.MANINDER DR.MANINDER AHUJA VP FOGSI2013-AHUJA VP FOGSI2013-20142014
2525
SPIROMETRYSPIROMETRY
• TLC
• Total lung capacity: the volume in the lungs at maximal inflation, the sum of VC and RV.
• TV
• Tidal volume: that volume of air moved into or out of the lungs during quiet breathing
• RV
• Residual volume: the volume of
air remaining in the lungs after a
maximal exhalation
• ERV
• Expiratory reserve volume: the
maximal volume of air that can
be exhaled from the end-
expiratory position
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 2626
Changes in Pulmonary funCtion Changes in Pulmonary funCtion tests in Acute Asthma tests in Acute Asthma
Decreased peak expiratory flow rate (PEFR) and forced expiratory volume in 1 second (FEV 1)
Mild reduction in the forced vital capacity (FVC)
An increased residual volume (RV), functional residual capacity (FRC), and total lung capacity (TLC)
Normal diffusing capacity
PEFR N 380-550 L/Min
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 2727
• Most pregnancies are Most pregnancies are unaccompanied by unaccompanied by pulmonary pulmonary complications, complications, however pulmonary however pulmonary edema, pulmonary edema, pulmonary thromboembolism, thromboembolism, pulmonary pulmonary hypertension, and hypertension, and acute respiratory acute respiratory failurefailure can occur can occur during pregnancy. during pregnancy. These conditions can These conditions can lead to mortality and lead to mortality and hence they should be hence they should be sought and treated sought and treated appropriately.appropriately.
17/12/1717/12/17DR.MANINDER DR.MANINDER AHUJA VP FOGSI2013-AHUJA VP FOGSI2013-20142014
2828
MANAGEMENT IN PREGMANAGEMENT IN PREG
• Lung function of women with persistent asthma should be monitored during pregnancy, using common pulmonary function parameters such as spirometry, the peak expiratory flow rate (PEFR), and forced expiratory volume in one second (FEV1).
• If possible, first-trimester ultrasound should also be performed to assess fetal growth restriction and risk of preterm birth. Starting at 32 weeks, ultrasound exams to monitor fetal activity and growth should be considered for women with poorly controlled asthma, moderate to severe asthma, or who are recovering from a severe asthma attack.
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 2929
MANAGEMENT CONT-MANAGEMENT CONT-
• Outpatient management of asthma is similar for the pregnant patient as it is for the nonpregnant patient
• . Beta-adrenergic agonists remain the mainstay of treating exacerbations and handling mild forms of asthma.
• Management algorithm for asthma in pregnancy based on fraction of exhaled nitric oxide (FENO) and symptoms significantly reduces asthma exacerbations.
• For moderate-persistent asthma, a beta-adrenergic agonist combined with an inhaled anti-inflammatory agent or inhaled corticosteroid is recommended for treatment. In severe asthma, oral corticosteroids and beta agonists are recommended.
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 3030
RECOMENDATIONSRECOMENDATIONS• Management geared Management geared
towards prevention of towards prevention of chronic symptomchronic symptom
• Pt should be educated Pt should be educated how to perform accurate how to perform accurate peakflowspeakflows
• + Action plan (Nelson, + Action plan (Nelson, Gossett, &Grobman, 2010)Gossett, &Grobman, 2010)
• + Monthly assessment in all + Monthly assessment in all asthmatic women with asthmatic women with evaluation of arterial sat >95% evaluation of arterial sat >95%
• ((Ivancso, Bohacs, Eszes, Losonczy, Ivancso, Bohacs, Eszes, Losonczy, &Tamasi, 2013)&Tamasi, 2013)
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 3131
Assess oxygenation by measuring the Assess oxygenation by measuring the arterial oxygen saturation of Hgbarterial oxygen saturation of Hgb
+ The proper use of a pulse oximeter can + The proper use of a pulse oximeter can ensure earlier detection of hypoxiaensure earlier detection of hypoxia
+ A normal Spo2 range is 95% to 100%+ A normal Spo2 range is 95% to 100%
Spo2 is one patient- assessment tool Spo2 is one patient- assessment tool and should be interpreted along with and should be interpreted along with
other patient data includingother patient data including+ Vital signs+ Vital signs
+ Cardiac rhythm+ Cardiac rhythm+ Breath sounds+ Breath sounds(Paragas, 2008)(Paragas, 2008)
PULSE OXIMETER (SPO2)
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 3232
Inhaler errors Inhaler errors
• Prior to adding therapy or increasing dosage, inhaler technique should be assessed and corrected. Up to one-third of dry powder inhaler users make insufficient inspiratory effort, and one-fourth of metered-dose inhaler users actuate before inhalation. These mistakes and others were associated with poor asthma control in the Critical Inhaler Mistakes and Asthma Control (CRITIKAL) study
•CRITIKAL study: type, frequency, and association with asthma outcomes. J Allergy Clin Immunol Pract. 2017;5(4):1071- 1081.e9
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 3333
OTHER MEDICATIONSOTHER MEDICATIONS
• The leukotriene receptor antagonists montelukast and zafirlukast are considered safe medications due to reassuring animal data
• Theophylline can be continued in pregnancy, but its use carries the added burden of monitoring to ensure that serum concentrations remain between 5 and 12 mg/mL to avoid toxicity
• Omalizumab pregnancy registry data (The Xolair Pregnancy Registry [EXPECT]) indicate no increase in major congenital malformations, but omalizumab should not be started in pregnancy due to risk of anaphylaxis
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 3434
Hospital managmentHospital managment
• Prehospial care Prehospial care
• Prior to arriving at the ED, address the patient’s airway status as needed. Provide early institution of beta-agonist inhalational therapy. Provide supplemental oxygen.
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 3535
In the In the emergencydepartment emergencydepartment
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 3636
Indications for Indications for admission admission
• As always in the ED, address the ABCs. The patient should be placed on a cardiac monitor and pulse oximetry. The threshold of intubation should be low to prevent/limit hypoxic episodes to the fetus. Intubate and mechanically ventilate patients who are in or near respiratory arrest and patients who do not respond to treatment
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 3737
Indications for Indications for intubation intubation
• Hypoxemia despite supplemental oxygen
• Increasing carbon dioxide retention
• Persistent/worsening level of consciousness
• Hemodynamic instability
• The key to treating asthma in the pregnant patient is to frequently assess the patient, the severity of the attack, and the response to treatment.
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 3838
Warning signs of severe Warning signs of severe exacerbationexacerbation
• Hypoxia, acidosis, unequal breath sounds, pneumothorax, and atypical features serve as warning signs of severe exacerbations.
• Inhaled beta2-agonists are the mainstay of treatment. The beta2-agonist, inhaled and/or subcutaneous, is typically given in 3 doses over 60-90 minutes.
• Beta-adrenergic blocking agents should be avoided owing to bronchospastic effect
• Tranquilizers and sedatives should be avoided because of their respiratory depressant effect. Antihistamines are not useful in the treatment of asthma. Mucolytic agents increase bronchospasm.
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 3939
Ventilator damageVentilator damage
• Asthmatic patients have higher complication rates from mechanical ventilation. Increased airway resistance may result in extremely high peak airway pressures, barotraumas, and hemodynamic impairment. Mucous plugging is common, increasing airway resistance, atelectasis, and the incidence of secondary pneumonia. Paradoxical increases in bronchospasm may occur from aggravation by the endotracheal tube.
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 4040
Criteria for hospital admissionCriteria for hospital admission
• Inadequate response to ED therapy
• pO 2 less than 70 mm Hg
• Signs of fetal distress (eg, decreased movement, abnormal cardio tocodynamometry, uterine contractions)
• Multiple medication use (ie, requiring 3 or more medications simultaneously)
• A protracted course with poor response to outpatient therapy thus far instituted or a history of severe asthma requiring intubation or ICU admission
• Inadequate home conditions and transport/access to ED care17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-
20142014 4141
Criteria for icuCriteria for icu
• Altered level of consciousness
• Poor air flow
• Signs of fatigue, a downhill course, or a need for mechanical ventilation
• PEFR/FEV 1 less than 25% of predicted or pCO 2greater than 35 mm Hg
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 4242
Criteria for discharge Criteria for discharge • Greatly improved symptoms and physical examination findings
• Ability of the patient to walk out of the ED without obvious distress
• PEFR/FEV 1 greater than 70% baseline
• No fetal distress
• Good follow-up and access to ED in case of relapse
• A follow-up appointment 2-4 days following the ED visit is recommended. Consider referral to an asthma specialist; in addition, involvement of a multidisciplinary team
• Guideline] American College of Obstetricians and Gynecologists (ACOG). Asthma in pregnancy. ACOG practice bulletin; no. 90. Washington (DC): American College of Obstetricians and Gynecologists (ACOG). 2008 Feb. [Full Text].
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 4343
Ventilator settingsVentilator settings
• Decrease the ratio of the duration of inspiration to the duration of expiration (I:E ratio), and set a low respiratory rate to allow for adequate expiration.
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 4444
Management of Acute Asthma Management of Acute Asthma in Pregnancy in Pregnancy
Intervene rapidly
Closely monitor the woman and assess fetal wellbeing continuously
Maintain oxygen saturation >95%
Avoid PaCO2 >40 mm Hg
Place woman in a left lateral position
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 4545
ContinuedContinued
Provide ample hydration with intravenous fluid (isotonic saline 125 ml/h) if drinking is impossible
Avoid hypotension with adequate position, hydration, and treatment
Use adrenaline (epinephrine) only in the context of an anaphylactic reaction
Consider intubation earlier than usual and call an expert if intubation is required as it can be more difficult in pregnant women owing to the oedema of the oropharyngeal mucosa
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 4646
Management of Management of acute exacerbationacute exacerbation
Beta2-agonist bronchodilation with one of the following:
• Albuterol MDI 4-8 puffs every 20 min up to 1 h, then every 1 to 4 hrs as needed
• Albuterol 0.083% 2.5-5 mg nebulized every 20 min for 3 doses, then every 1 to 4 h as needed
• Cont nebulization 10-15mg /hr
• Anticholinergics added to beta2-agonist therapy
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 4747
Cont ---Cont ---
• Ipratropium bromide/Anticholinergic nebulized 0.5 mg every 20 minutes for 3 doses, then as needed, given simultaneously with albuterol
• Oxygen
• Fetal Monitoring
• Oral or I/V Hydrations
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 4848
Cont –Cont –glucocorticoidsglucocorticoids
• Systemic Gluco corticosteroids if pt was already on CS
• Mild exacerbation that can be managed safely at home: oral prednisone 40 to 60 mg/d for 3 to 10 day
• Hospitalisation till PEF is 70% of predicted
• Critically ill: high-dose IV methylprednisolone 120-180 mg/d in three or four divided doses for 48 h, then 60-80 mg/d, tapered as patient improves
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 4949
Cont –adjuNct Cont –adjuNct therapies therapies
• Adjunct therapies for patients poorly responsive to the above:
• Magnesium sulfate 2 g IV over 20 minutes. Assess baseline serum magnesium level if renal insufficiency present
• Terbutaline 0.25 mg subcutaneous every 20 min for up to three doses
• Plan early and expert intubation and mechanical ventilation for patients in severe distress poorly responsive to the above, or who exhibit arterial pH < 7.35, arterial PCO2 above the normal pregnancy range of 28-32 mm Hg, or arterial PO2 < 70
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 5050
Cont -– monitor Cont -– monitor ventilation ventilation
• Titrate ventilation to achieve normal pH, normal pregnancy PCO2 of 28-32 mm Hg, and normal PO2. If hyperinflation does not permit titration to normal pregnancy PCO2, hypercapnia may be tolerated.
• For patients who fail the aforementioned ventilator strategies and maximum pharmacologic treatments, extracorporeal membrane oxygenation (ECMO) has been described in nonpregnant patients with asthma91 and in one case report of a pregnant woman with asthma.
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 5151
ACOG Guidelines ACOG Guidelines -2008-2008
• Pregnant asthmatic women should continue to use their asthma medication in the lowest dose possible to manage symptoms during pregnancy, according to a new Practice Bulletin released by The American College of Obstetricians and Gynecologists (ACOG). Women with moderate or severe asthma should also be monitored throughout pregnancy for fetal growth restriction and signs of preterm birth.
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 5252
Anti Asthma MedicationsAnti Asthma Medications
Almost all antiasthma drugs are safe to use in pregnancy and during breastfeeding.
In fact, undertreatment of the pregnant patient is a frequent occurrence, because such patients are worried about medication effects on the fetus.
Rey E, Boulet LP. Asthma in pregnancy. BMJ. 2007 Mar 17. 334(7593):582-5. [Medline]. [Full Text].
Powell H, Murphy VE, Taylor DR, et al. Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial. Lancet. 2011 Sep 10. 378(9795):983-90. [Medline].
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 5353
SYSTEMIC CORTICOSTEROIDSSYSTEMIC CORTICOSTEROIDS
• BECAUSE SEVERE, BECAUSE SEVERE, UNCONTROLLED ASTHMA UNCONTROLLED ASTHMA IS ASSOCIATED WITH IS ASSOCIATED WITH MATERNAL/FETAL DEATH, MATERNAL/FETAL DEATH, THE USE OF SYSTEMIC THE USE OF SYSTEMIC CORTICOSTEROIDS CORTICOSTEROIDS ALTHOUGH RISKY, IS ALTHOUGH RISKY, IS JUSTIFIED WHEN SEVERE JUSTIFIED WHEN SEVERE ASTHMA CANNOT BE ASTHMA CANNOT BE CONTROLLED BY OTHER CONTROLLED BY OTHER MEANSMEANS
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 5454
Medications during Medications during LabourLabour
Continue medications and give short acting β2 agonists or corticosteroids, or both, if asthma is not well controlled
Provide ample hydration with intravenous fluid
Evaluate pulmonary status and oxygen saturation on admission, and later as needed
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 5555
Management in Management in LabourLabour
Favour epidural to provide pain relief (which decreases bronchospasm) and to reduce oxygen consumption and minute ventilation
Stress dose of corticosteroids (such as 50-75 mg a day of hydrocortisone equivalent for one to two days if systemic corticosteroids have been taken within previous months
Avoid bronchoconstrictor agents for management of abortion or labour (such as prostaglandin F2 ) or for αpostpartum haemorrhage (such as ergonovine, methylergonovine (neither is licensed in the UK), and carboprost)
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 5656
Asthma and Post PartumAsthma and Post Partum
The postpartum period is not associated with an increased rate of asthma exacerbations.
In women who experienced a change of severity during pregnancy, the severity reverts to pre-pregnancy level within three months after the birth
Irritability or sleepiness have been reported in the breastfed neonates of women taking theophylline and antihistamines.
Non-steroidal anti-inflammatory drugs should be avoided in women intolerant to aspirin.
Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. Seventh ed. Philadelphia: 2005.
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 5757
ASTHMA… ALMOST ALWAYS ASSOCIATED WITH ASTHMA… ALMOST ALWAYS ASSOCIATED WITH NASAL DISEASE.NASAL DISEASE.
• Treatment of the upper airway should improve asthma for a variety of reasons
• Mechanisms linking the development or exacerbation of asthma in individuals with upper airway disease may be multifactorial
• (Ledford &Lockey, 2013).
RELEASE OF SYSTEMIC IMMUNE MEDIATORS FROM THE UPPER
• AIRWAY, DRAINAGE OF• INFLAMMATORY MEDIATORS FROM
THE UPPER AIRWAY INTOTHE LOWER AIRWAY
• + NEUROGENIC RESPONSES RESULTING IN MORE GENERALIZED
• AIRWAY INFLAMMATION OR• COMMON INHALANT MECHANISMS
WITH ALLERGENS CAUSING INFLAMMATION INITIALLY INTHE UPPER AIRWAY FOLLOWED BY THE LOWER AIRWAY INVOLVEMENT.
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 5858
For rhinitis For rhinitis
• Leukotriene receptor antagonists such as montelukast are generally accepted as safe.
• Intranasal antihistamines or oral second-generation antihistamines, including cetirizine or loratadine, are also considered safe.61 Local vasoconstriction with oxymetazoline can be used, at usual dosing for # 3 days to avoid rebound rhinitis.
• However, oral decongestants such as pseudoephedrine and phenylephrine should be avoided, especially in early pregnancy, as their systemic vasoconstriction has teratogenic effects.
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 5959
FACT SHEET FACT SHEET • Samita is a 36 years old woman currently in her 26th week of
pregnancy with a history of allergic rhinitis and seasonal allergies who appeared more tired for the past month and has shown progressive shortness of breath and wheezing for the past couple of weeks.
• During a recent doctors visit, her primary care physician prescribed an albuterol asthma pump which she didn’t use due to fear to harm the baby.
• A week later she returned to the same doctor who in turn prescribed an albuterol nebulizer treatment along with a nebulizer machine and some prednisone pills in case her shortness of breath got worst.
• Because of fear to harm the baby Jenny decided to use the nebulizer treatment and asthma pump and avoid the prednisone at all costs.
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 6060
PREGNANT WOMAN MAY OFTEN WORRY ABOUT EFFECTS OF THEIR ASTHMA PREGNANT WOMAN MAY OFTEN WORRY ABOUT EFFECTS OF THEIR ASTHMA MEDICATIONS, AND MAY DISCONTINUE THEM INAPPROPRIATELY…MEDICATIONS, AND MAY DISCONTINUE THEM INAPPROPRIATELY…””
((NELSON, GOSSETT, &GROBMAN, NELSON, GOSSETT, &GROBMAN, 2010)2010)
• Short-acting beta-agonists for Short-acting beta-agonists for immediate relief of asthma immediate relief of asthma symptoms during pregnancy symptoms during pregnancy is generally regarded as is generally regarded as being safe being safe (Ulrik&Gregersen, 2013)(Ulrik&Gregersen, 2013)
• Inhaled corticosteroids are Inhaled corticosteroids are the mainstay of controller the mainstay of controller therapy during pregnancy. therapy during pregnancy. ICS(Namazy&ICS(Namazy&
• Schatz, 2011)Schatz, 2011)
• Budesonide is Budesonide is considered the considered the preferred ICS for preferred ICS for asthma during asthma during pregnancypregnancy
• Most medications used Most medications used for asthma for asthma for asthma for asthma treatment outside of treatment outside of pregnancy are also not pregnancy are also not contraindicated during contraindicated during pregnancypregnancy (Nelson, Gossett, (Nelson, Gossett, &Grobman, 2010&Grobman, 2010
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 6161
Co morbidities aggaravating Co morbidities aggaravating asthmaasthma
• Sinusitis and Reflux are relatively common Sinusitis and Reflux are relatively common comorbiditiescomorbidities during pregnancy that may during pregnancy that may exacerbate asthma.exacerbate asthma.
• Pregnancy may be complicated by new-onset Pregnancy may be complicated by new-onset or preexisting rhinitis, or asthma.or preexisting rhinitis, or asthma.
• + + Rhinitis is a very common problem that may Rhinitis is a very common problem that may occur during pregnancy. In the past, rhinitis occur during pregnancy. In the past, rhinitis and asthma may have been treated as and asthma may have been treated as separate disorders.separate disorders.
• + + The United Airway Disease Hypothesis proposes that upper and lower The United Airway Disease Hypothesis proposes that upper and lower airway disease are both manifestations of a single inflammatory process.airway disease are both manifestations of a single inflammatory process.
• (Namazy& Schatz, 2011(Namazy& Schatz, 2011
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 6262
MMAJOR GOAL OF CHRONIC ASTHMA MANAGEMENT IS AJOR GOAL OF CHRONIC ASTHMA MANAGEMENT IS THE PREVENTION OF EXACERBATIONTHE PREVENTION OF EXACERBATION
• Pharmacologic approach:Pharmacologic approach:• + + Inhaled Beta2-agonist (Albuterol)Inhaled Beta2-agonist (Albuterol)• + + Inhaled Corticosteroids (Budesonide)Inhaled Corticosteroids (Budesonide)• + + Alternative add-on medication (long-acting beta2-Alternative add-on medication (long-acting beta2-
agonist, cromolyn,agonist, cromolyn,
• leukotriene inhibitor, theophyline)leukotriene inhibitor, theophyline)• (National Guideline Clearinghouse, 2012)(National Guideline Clearinghouse, 2012)• + + Acute managementAcute management• + + Pharmacologic approach / step therapyPharmacologic approach / step therapy• + + Fetal monitoring / maternal monitoring.Fetal monitoring / maternal monitoring.• + + Supplemental O2 to maintain PO2 > 70 and O2 sat Supplemental O2 to maintain PO2 > 70 and O2 sat
>95% by pulseoximetry.>95% by pulseoximetry.• + + IV fluids at rate of 100ml/hour with glucose if pt not IV fluids at rate of 100ml/hour with glucose if pt not
hyperglycemic.hyperglycemic. 17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 6363
Special considerations in Special considerations in Preg with Asthma Preg with Asthma
• Ensure optimal asthma control
• Manage asthma exacerbations aggressively
• Avoid delay in diagnosis and treatment
• Assess medication needs and response to therapy frequently
• Ensure adequate patient education and acquisition of self management skills
• Treat rhinitis, gastric reflux, and other comorbidities adequately
Encourage smoking cessation
Assess pulmonary function (expiratory flow) with spirometry at least monthly
Offer a multidisciplinary team approach
Do not give flu vaccination until after 12 weeks of pregnancy
Be aware of the risk of pre-eclampsia and intrauterine growth retardation
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 6464
Conclusions Conclusions
Asthma may be influenced by pregnancy, but the outcome and prognosis of most asthmatic mothers and their newborn infants are usually favourable, particularly if the women's asthma is well controlled in pregnancy.
Exacerbations should be prevented by optimal asthma management,
Treatment should be started before pregnancy to educate and prevent exacerbation in preg so that asthma does not become transgeneration
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 6565
I Am On A Mission For FOGSI !
Support For FOGSI President 2018 Elections
Dr. Maninder Ahuja Mobi le :9810881048
E,mail .ahuja.manider@gmil .com MBBS, DGO, FICOG ,CIMP, Dip of IAN DONALD School of US
PROF. MANINDER AHUJA
17/12/1717/12/17DR.MANINDER AHUJA VP FOGSI2013-DR.MANINDER AHUJA VP FOGSI2013-20142014 6666